Anti-pituitary antibodies and hypogonadotropic hypogonadism in type 2 diabetes: in search of a role.

Subnormal testosterone concentrations have been found in 25% of men with type 2 diabetes in association with inappropriately low luteinizing hormone and follicle-stimulating hormone concentrations (1), which suggests that the primary defect may be at the hypothalamo-hypophyseal level. Circulating anti-pituitary antibodies (APAs) were first detected by Kobayashi et al. (2) in sera from 91 patients with type 2 diabetes at a relatively high frequency (24.2%). Thus far, a possible role of pituitary autoimmunity in diabetic patients with hypogonadotropic hypogonadism (HH) has never been investigated.

Ninety-five consecutive male patients with type 2 diabetes and aged >35 years were recruited among those attending the Unit of Endocrinology and Metabolic Diseases at the Second University of Naples from September 2010 to September 2012. Patients with severe obesity (BMI >35 kg/m2) were excluded. The diagnosis of isolated HH included a serum testosterone level <12.0 nmol/L, normal or low gonadotropin concentrations, and symptoms and signs of androgen deficiency. Erectile dysfunction was diagnosed in the presence of an International Index of Erectile Dysfunction-5 score <21. APAs were assessed by an indirect immunofluorescence method on cryostat sections of young baboon pituitary gland (3). Immunostaining patterns were classified as type 1 (cytoplasmatic fluorescence of few pituitary cells) and type 2 (diffuse fluorescence in almost all cells in the pituitary section) (4).

Thirty-seven diabetic patients had HH (group 1), and none showed alteration of resonance magnetic imaging at the hypothalamic-pituitary region. Compared with 100 age-matched control subjects (Table 1), all diabetic patients showed an increased prevalence of APAs (26/95, 27.3%, P < 0.001), which was highest in group 1 (15/37, 40%, P = 0.002 vs. group 2). High titers (≥1/16) of APAs were detected in all patients of group 1, with a type 1 immunostaining pattern; in group 2 (no HH), 10 of 11 patients presented APAs at low titer (<1/8), with most presenting a type 2 immunofluorescence pattern. In both groups 1 and 2, APAs were detected the most (70–80%) in newly diagnosed patients. APAs selectively immunostained gonadotrophs and only rarely some prolactin-secreting cells in group 1, whereas in group 2 none immunostained gonadotropin-secreting cells.

Table 1

Characteristics of type 2 diabetic patients and control subjects

Our results confirm the high prevalence of HH in patients with type 2 diabetes and suggest a possible autoimmune pathogenesis of HH in some of them, as indicated by the presence of APAs at high titers with an immunostaining pattern predictive of hypopituitarism (4) and supported by the identification of these antibodies as targeting gonadotropin-secreting cells. We also found the highest APA prevalence in HH patients with newly diagnosed diabetes; this suggests that some APAs may be harmless and tend to disappear over time, whereas others, which persist over time, can exert biological function. This may also explain the results of Takeda et al. (5), who found APAs in only 2.2% of type 2 diabetic patients with long duration of disease (>10 years on the average). Prospective studies are needed in order to clarify the natural history of HH in type 2 diabetes and whether APAs may play a significant role.